Tetrahydroaminoacridine in HIV infections. The THA Study Group.
On the basis of a similarity between certain neurological symptoms of AIDS and Alzheimer's disease, the authors studied the effects of tetrahydroaminoacridine (THA) in 9 patients with HIV infection. After 2 months of treatment, the preliminary results showed a significant increase in CD4 lymphocyte count as well as a decrease in p24 antigen level in 8 patients, of whom 4 became negative for the p24 antigen.
Fredj
G
G
Hôpital Paul Brousse, Villejuif, France.
Dietlin
F
F
Fredj
D
D
Schwarzenberg
L
L
Jasmin
C
C
Meyer
P
P
Misset
J L
JL
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000609:Aminoacridines / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D015704:CD4 Antigens / Q000032:analysis; D005260:Female; D015488:HIV Antigens / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000517:prevention & control; D013619:Tacrine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000609:Aminoacridines; D015704:CD4 Antigens; D015488:HIV Antigens; D013619:Tacrine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase